PANTHERx Selected as Exclusive U.S. Pharmacy Partner for IMCIVREE Distribution
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy RYTM?
Source: Newsfilter
- Exclusive Partnership: PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE, focusing on acquired hypothalamic obesity, which marks a significant expansion in the company's rare disease portfolio and is expected to enhance its market share and brand influence.
- Personalized Patient Support: PANTHERx will leverage its industry-leading RxARECARE® model to provide personalized clinical support and education to patients, caregivers, and prescribers, aiming to simplify the complex treatment processes associated with rare diseases and improve patient adherence and satisfaction.
- Historic Milestone: The new indication for IMCIVREE offers crucial treatment options for patients with acquired hypothalamic obesity, with CEO Bansi Nagji highlighting that this advancement brings hope to affected individuals and families, further solidifying the company's leadership in rare disease therapies.
- Industry Recognition: Since 2020, PANTHERx has been the exclusive pharmacy partner for IMCIVREE, focusing on obesity related to conditions like Bardet-Biedl Syndrome, and the company's successful track record and expertise will provide robust support for the promotion of this new indication.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 96.230
Low
123.00
Averages
140.62
High
167.00
Current: 96.230
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stock Investment Opportunities in May
- TransMedics' Bright Outlook: Despite TransMedics Group (NASDAQ: TMDX) reporting Q1 earnings per share of $0.30, below the expected $0.61, its revenue increased by 21% year-over-year, indicating strong long-term potential in organ transplant technology, especially with plans for European expansion.
- Rhythm Pharmaceuticals' Recovery: Rhythm Pharmaceuticals (NASDAQ: RYTM) recently secured FDA and European Commission approvals for Imcivree, which is expected to boost its stock price, while Japanese regulators are also reviewing the drug, impacting over 25,000 patients and highlighting significant market potential.
- Enbridge's Stable Returns: Enbridge (NYSE: ENB), as North America's largest natural gas utility, transports 30% of crude oil and one-fifth of natural gas, providing stable investment returns, with an attractive 5.2% dividend yield that stands out in the energy sector.
- Long-Term Growth Opportunities: Enbridge's management anticipates approximately $50 billion in growth opportunities by 2030, with investment decisions for $10 billion to $20 billion expected in the next 24 months, offering solid growth prospects despite being less explosive than TransMedics and Rhythm.
See More
Rhythm Pharmaceuticals Reports Strong Earnings, IMCIVREE Demand Surges
- Earnings Beat Expectations: Rhythm Pharmaceuticals reported quarterly earnings that exceeded market expectations, reflecting strong performance in drug sales, which is likely to boost investor confidence moving forward.
- Strong Demand for IMCIVREE: The demand for IMCIVREE continues to grow, driving revenue increases and indicating a rising market acceptance of the drug in the treatment landscape, potentially laying the groundwork for future revenue growth.
- International Market Expansion Potential: The company plans to launch IMCIVREE in Europe and Japan, and successful entry into these markets could significantly broaden its international business footprint and enhance its competitive position globally.
- Strategic Growth Outlook: Rhythm Pharmaceuticals' robust performance and international expansion plans suggest that its strategic decisions to meet global patient needs will contribute to long-term growth and an increase in market share.
See More
Rhythm Pharmaceuticals Surges 8% After Strong Quarterly Earnings Report
- Significant Revenue Growth: Rhythm Pharmaceuticals reported a nearly doubled revenue of $60.1 million in Q1, driven by its Imcivree drug, surpassing the analyst consensus estimate of $57 million, indicating strong market performance in the weight-loss sector.
- Improved Net Loss: The company's net loss widened to $56.7 million (or $0.83 per share), yet it was better than the expected loss of $0.86, suggesting some progress in cost management despite increased expenses.
- Accelerated Market Promotion: Following FDA approval for a new indication (hypothalamic obesity), Imcivree received over 150 patient start forms within six weeks, demonstrating robust market demand and rapid promotional capabilities.
- Strong European Market Performance: Rhythm's revenue in Europe surged by 27% quarter-over-quarter, primarily driven by strong demand in key markets like Germany and France, further boosting investor confidence in the company's growth prospects.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: Rhythm Pharmaceuticals reported global net revenues of $60.1 million for Q1 2026, reflecting a 5% sequential increase from Q4 2025, indicating robust market performance, particularly with 61% of revenue generated in the U.S.
- IMCIVREE Launch Status: Since the FDA approval of IMCIVREE, the company has received over 150 start forms, with approximately 80% coming from new prescribers, demonstrating strong market reception and potential for future revenue growth.
- R&D and Expense Outlook: The company anticipates non-GAAP operating expenses for fiscal year 2026 to be between $385 million and $415 million, with R&D expenses projected at $197 million to $213 million, reflecting a commitment to ongoing product development.
- International Market Progress: Rhythm's NDA filing in Japan has been accepted, with approval and launch expected by the end of 2026, further expanding its international presence and enhancing the company's global competitiveness.
See More
RHYTHM PHARMACEUTICALS STOCK JUMPS 7.5% IN PREMARKET TRADING FOLLOWING Q1 REVENUE INCREASE
- Company Performance: Rhyme Pharmaceutical's shares increased by 7.5% in pre-market trading following the release of their Q1 revenue report.
- Revenue Growth: The company reported a rise in revenue for the first quarter, contributing to the positive market response.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Report Analysis
- Earnings Performance: Rhythm Pharmaceuticals reported a Q1 2026 GAAP EPS of -$0.83, in line with expectations, while revenue reached $60.1 million, a 59.4% year-over-year increase, exceeding forecasts by $4.03 million, indicating strong growth momentum in the market.
- Cash Flow Status: As of March 31, 2026, the company had approximately $340.6 million in cash, cash equivalents, and short-term investments, down from $388.9 million as of December 31, 2025, reflecting challenges in cash management.
- FDA Approval Progress: Rhythm Pharmaceuticals discussed the FDA approval of IMCIVREE for acquired hypothalamic obesity, marking a significant advancement in drug development that could provide new revenue growth opportunities in the future.
- Clinical Trial Results: The company shared topline results and insights from the Phase 3 EMANATE trial, further solidifying its R&D capabilities in obesity treatment, which is expected to positively impact market confidence.
See More
Stock Investment Opportunities in May
- TransMedics' Bright Outlook: Despite TransMedics Group (NASDAQ: TMDX) reporting Q1 earnings per share of $0.30, below the expected $0.61, its revenue increased by 21% year-over-year, indicating strong long-term potential in organ transplant technology, especially with plans for European expansion.
- Rhythm Pharmaceuticals' Recovery: Rhythm Pharmaceuticals (NASDAQ: RYTM) recently secured FDA and European Commission approvals for Imcivree, which is expected to boost its stock price, while Japanese regulators are also reviewing the drug, impacting over 25,000 patients and highlighting significant market potential.
- Enbridge's Stable Returns: Enbridge (NYSE: ENB), as North America's largest natural gas utility, transports 30% of crude oil and one-fifth of natural gas, providing stable investment returns, with an attractive 5.2% dividend yield that stands out in the energy sector.
- Long-Term Growth Opportunities: Enbridge's management anticipates approximately $50 billion in growth opportunities by 2030, with investment decisions for $10 billion to $20 billion expected in the next 24 months, offering solid growth prospects despite being less explosive than TransMedics and Rhythm.
See More
Rhythm Pharmaceuticals Reports Strong Earnings, IMCIVREE Demand Surges
- Earnings Beat Expectations: Rhythm Pharmaceuticals reported quarterly earnings that exceeded market expectations, reflecting strong performance in drug sales, which is likely to boost investor confidence moving forward.
- Strong Demand for IMCIVREE: The demand for IMCIVREE continues to grow, driving revenue increases and indicating a rising market acceptance of the drug in the treatment landscape, potentially laying the groundwork for future revenue growth.
- International Market Expansion Potential: The company plans to launch IMCIVREE in Europe and Japan, and successful entry into these markets could significantly broaden its international business footprint and enhance its competitive position globally.
- Strategic Growth Outlook: Rhythm Pharmaceuticals' robust performance and international expansion plans suggest that its strategic decisions to meet global patient needs will contribute to long-term growth and an increase in market share.
See More
Rhythm Pharmaceuticals Surges 8% After Strong Quarterly Earnings Report
- Significant Revenue Growth: Rhythm Pharmaceuticals reported a nearly doubled revenue of $60.1 million in Q1, driven by its Imcivree drug, surpassing the analyst consensus estimate of $57 million, indicating strong market performance in the weight-loss sector.
- Improved Net Loss: The company's net loss widened to $56.7 million (or $0.83 per share), yet it was better than the expected loss of $0.86, suggesting some progress in cost management despite increased expenses.
- Accelerated Market Promotion: Following FDA approval for a new indication (hypothalamic obesity), Imcivree received over 150 patient start forms within six weeks, demonstrating robust market demand and rapid promotional capabilities.
- Strong European Market Performance: Rhythm's revenue in Europe surged by 27% quarter-over-quarter, primarily driven by strong demand in key markets like Germany and France, further boosting investor confidence in the company's growth prospects.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: Rhythm Pharmaceuticals reported global net revenues of $60.1 million for Q1 2026, reflecting a 5% sequential increase from Q4 2025, indicating robust market performance, particularly with 61% of revenue generated in the U.S.
- IMCIVREE Launch Status: Since the FDA approval of IMCIVREE, the company has received over 150 start forms, with approximately 80% coming from new prescribers, demonstrating strong market reception and potential for future revenue growth.
- R&D and Expense Outlook: The company anticipates non-GAAP operating expenses for fiscal year 2026 to be between $385 million and $415 million, with R&D expenses projected at $197 million to $213 million, reflecting a commitment to ongoing product development.
- International Market Progress: Rhythm's NDA filing in Japan has been accepted, with approval and launch expected by the end of 2026, further expanding its international presence and enhancing the company's global competitiveness.
See More
RHYTHM PHARMACEUTICALS STOCK JUMPS 7.5% IN PREMARKET TRADING FOLLOWING Q1 REVENUE INCREASE
- Company Performance: Rhyme Pharmaceutical's shares increased by 7.5% in pre-market trading following the release of their Q1 revenue report.
- Revenue Growth: The company reported a rise in revenue for the first quarter, contributing to the positive market response.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Report Analysis
- Earnings Performance: Rhythm Pharmaceuticals reported a Q1 2026 GAAP EPS of -$0.83, in line with expectations, while revenue reached $60.1 million, a 59.4% year-over-year increase, exceeding forecasts by $4.03 million, indicating strong growth momentum in the market.
- Cash Flow Status: As of March 31, 2026, the company had approximately $340.6 million in cash, cash equivalents, and short-term investments, down from $388.9 million as of December 31, 2025, reflecting challenges in cash management.
- FDA Approval Progress: Rhythm Pharmaceuticals discussed the FDA approval of IMCIVREE for acquired hypothalamic obesity, marking a significant advancement in drug development that could provide new revenue growth opportunities in the future.
- Clinical Trial Results: The company shared topline results and insights from the Phase 3 EMANATE trial, further solidifying its R&D capabilities in obesity treatment, which is expected to positively impact market confidence.
See More
